Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151148 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL7451532 | 0.97 | KDM4E (0.34) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL7451527 | 0.97 | KDM4E (0.34) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6962187 | 0.97 | RAB9A (0.38) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL6961595 | 0.80 | RAB9A (0.42) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL21428543 | 0.78 | — | — | |
| SCHEMBL6960389 | 0.78 | RAB9A (0.41) | KDM4EALDH1A1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL21428536 | 0.75 | SIGMAR1 (0.30) | — | |
| SCHEMBL21428541 | 0.75 | MAPK1 (0.31) | KDM4EALDH1A1SMN1; SMN2TDP1MAPK1 | |
| SCHEMBL22482242 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| EP-1195376-B1 | Azoamidine compounds and their use as polymerization initiators | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-6403774-B1 | WATER SOLUBLE POLYMERIZATION INITIATOR. | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1195376-A1 | Azoamidine compounds and their use as polymerization initiators | Wako Pure Chemical Industies, Ltd. (JP) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | XBP1, ERN1, ERN2 | KDM4E 1147/4885ALDH1A1 2686/4885RAB9A 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.